Comparison of the Metabolic Effects of Raloxifene and Oral Estrogen in Postmenopausal and Growth Hormone-Deficient Women
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
CONTEXT: The endocrine and metabolic functions of the liver are affected by estrogen. Oral estrogen reduces IGF-I and suppresses fat oxidation despite augmenting GH secretion. The aim of this study was to determine whether selective estrogen receptor modulators display similar effects and whether these effects are magnified in GH-deficient (GHD) women because of the loss of GH feedback. DESIGN: This was an open-label, randomized, two-period, crossover study comparing treatment (raloxifene vs. estradiol) and group (normal vs. GHD). SETTING: The setting of this study was a clinical research unit. PARTICIPANTS: Twelve postmenopausal women and 12 women with hypopituitarism participated in this study. INTERVENTION: Two 4-wk treatments with 17beta-estradiol (E2; 2 mg, followed by 4 mg) or raloxifene (60 mg, followed by 120 mg) were given, crossing over to the alternate treatment after a 4-wk washout period. OUTCOME MEASURES: Endocrine [GH, IGF-I, IGF-binding protein-3 (IGFBP-3), GH-binding protein, and SHBG] and metabolic (fat oxidation) end points were used as outcome measures. RESULTS: E2 reduced serum IGF-I levels in a dose-dependent manner in both groups, with effects greater (P < 0.05) than raloxifene. Raloxifene reduced IGF-I levels in the GHD group (P < 0.001), but not in the postmenopausal group. E2 reduced (P < 0.05), and raloxifene increased (P < 0.05), IGFBP-3 levels in both groups. E2, but not raloxifene, increased GH (P < 0.05) in postmenopausal women. The effects of E2 and raloxifene on IGF-I, IGFBP-3, IGF-I/IGFBP-3 molar ratio, GH-binding protein, and SHBG were significantly different (P < 0.05). E2 and raloxifene reduced (P < 0.05) fat oxidation equally in GHD, whereas the decrease in postmenopausal women was not significant. CONCLUSION: E2 and raloxifene exert different hepatic endocrine, but not lipid oxidative, effects. The greater effects seen in GHD women may be explained by the loss of endogenous GH feedback.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One study showed that women on oral estrogen might require a GH replacement dose up to 50% higher compared with women or men who are not on estrogen (199).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [199]
Citations
Cites
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., & Pollak, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10384-1 · Cited by 1,823 · cited 1×
“with an increased risk of the development of breast (27),”
BackgroundThe theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,580 · cited 1×
“This value was estimated based on body weight, as previously described (12).”
MethodMa, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, Y., Hennekens, C. H., & Stampfer, M. J. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.620 · Cited by 1,119
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 968 · cited 1×
“trogen agonistic and antagonistic activities (5).”
Cummings, S. R. (1999) · Medical Entomology and Zoology · Cited by 797
Effect of Growth Hormone on Carbohydrate and Lipid Metabolism
DAVIDSON, M. B. (1987) · Endocrine Reviews · doi:10.1210/edrv-8-2-115 · Cited by 573 · cited 1×
“oxidation (23), the absence of compensatory stimulation ren-”
BackgroundEstrogen Regulation of Growth Hormone Action
Leung, K.-C., Johannsson, G., Leong, G. M., & Ho, K. K. Y. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0035 · Cited by 542 · cited 1×
“After binding to and dimerization of its receptor, GH increases IGF-I production through stimulation of the cytokine-signaling (Janus kinasesignal transducer and activator of transcription) pathway (32).”
BackgroundSelf-citationWEISSBERGER, A. J., HO, K. K. Y., & LAZARUS, L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-2-374 · Cited by 514
Self-citationThe Diagnosis of Growth Hormone Deficiency in Adults
Ho, K. K. Y., & Hoffman, D. M. (1997) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.6.suppl10_35 · Cited by 428
Self-citationSelective Estrogen Receptor Modulators
Frasor, J., Stossi, F., Danes, J. M., Komm, B., Lyttle, C. R., & Katzenellenbogen, B. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3326 · Cited by 395
Diagnosis of growth-hormone deficiency in adults
Hoffman, D. M., O'Sullivan, A. J., Ho, K. K. Y., & Baxter, R. C. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90181-3 · Cited by 386
Self-citationSerum Estradiol Level and Risk of Breast Cancer During Treatment With Raloxifene
Cummings, S. R. (2002) · JAMA · doi:10.1001/jama.287.2.216 · Cited by 219 · cited 1×
“A low ratio may confer an antitumorigenic effect, consistent with the observation that SERMs protect against breast cancer recurrence and progression (30, 31).”
ResultLeung, K. C., Doyle, N., Ballesteros, M., Sjogren, K., Watts, C. K. W., Low, T. H., Leong, G. M., Ross, R. J. M., & Ho, K. K. Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337600100 · Cited by 218 · cited 1×
“We have shown that in a number of cell lines, including one derived from hepatocytes, estrogen increases SOCS-2 mRNA, and that in cells devoid of SOCS-2, the inhibitory effects of estrogen on GH signaling were abolished (33).”
BackgroundSelf-citationO'Sullivan, A. J., Crampton, L. J., Freund, J., & Ho, K. K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2773 · Cited by 210
Self-citationChin, E. (1994) · Endocrinology · doi:10.1210/en.134.6.2498 · Cited by 174
Kelly, J. J., Rajkovic, I. A., O'Sullivan, A. J., Sernia, C., & Ho, K. K. Y. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb02410.x · Cited by 167
Self-citationCirculating binding proteins for the insulinlike growth factors
Baxter, R. C. (1993) · Trends in Endocrinology & Metabolism · doi:10.1016/1043-2760(93)90085-s · Cited by 160
de Valk-de Roo, G. W., Stehouwer, C. D. A., Meijer, P., Mijatovic, V., Kluft, C., Kenemans, P., Cohen, F., Watts, S., & Netelenbos, C. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.12.2993 · Cited by 158 · cited 1×
“profile and coagulation factors (6) suggest that the hepatic”
BackgroundCook, D. M., Ludlam, W. H., & Cook, M. B. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6113 · Cited by 129 · cited 1×
“T A FIRST-PASS hepatic effect, orally administered estrogen reduces circulating IGF-I (1, 2), in-”
BackgroundOral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women
Wolthers, T., Hoffman, D. M., Nugent, A. G., Duncan, M. W., Umpleby, M., & Ho, K. K. Y. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1191 · Cited by 114 · cited 3×
“The influence of estrogens on the GH/IGF-I axis is dose dependent and is dictated by effects exerted on the liver (2, 4, 15).”
BackgroundSelf-citationCook, D. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.11.3956 · Cited by 92
Reutens, A. T. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.2.480 · Cited by 81
Self-citationAndersson, B. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.1.122 · Cited by 57 · cited 2×
“Although recent studies have demonstrated that raloxifene reduces IGF-I in healthy postmenopausal (7, 8), type 2 diabetic (9), and acromegalic (10) women, little is known about whether it affects hepatic metabolism, or how the effects of raloxifene on the GH/IGF-I system compare with those of oral estrogen.”
BackgroundSelf-citationBarrett-Connor, E. L., Ensrud, K. E., Harper, K. D., Mason, T. M., Sashegyi, A. I., Krueger, K. A., & Anderson, P. W. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80114-5 · Cited by 56 · cited 2×
“Although recent studies have demonstrated that raloxifene reduces IGF-I in healthy postmenopausal (7, 8), type 2 diabetic (9), and acromegalic (10) women, little is known about whether it affects hepatic metabolism, or how the effects of raloxifene on the GH/IGF-I system compare with those of oral estrogen.”
BackgroundRaloxifene decreases serum IGF-I in male patients with active acromegaly
Dimaraki, E. V., Symons, K. V., & Barkan, A. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500481 · Cited by 49 · cited 1×
“Raloxifene has been shown to reduce IGF-I in healthy postmenopausal women (7, 8), women with breast cancer (16), and men and women with acromegaly (17, 18).”
BackgroundRajkovic, I. A., Valiontis, E., & Ho, K. K. Y. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.3.8126156 · Cited by 46
Self-citationEffect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer
Torrisi, R., Baglietto, L., Johansson, H. A., Veronesi, G., Bonanni, B., Guerrieri‐Gonzaga, A., Ballardini, B., & DeCensi, A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2191 · Cited by 40 · cited 1×
“Raloxifene has been shown to reduce IGF-I in healthy postmenopausal women (7, 8), women with breast cancer (16), and men and women with acromegaly (17, 18).”
BackgroundRaloxifene lowers IGF-I levels in acromegalic women
Attanasio, R., Barausse, M., & Cozzi, R. C. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480443 · Cited by 38 · cited 1×
“Raloxifene has been shown to reduce IGF-I in healthy postmenopausal women (7, 8), women with breast cancer (16), and men and women with acromegaly (17, 18).”
BackgroundDifferential Effects of Raloxifene and Estrogen on Insulin Sensitivity in Postmenopausal Women
Lee, C. C., Kasa‐Vubu, J. Z., & Supiano, M. A. (2003) · Journal of the American Geriatrics Society · doi:10.1034/j.1600-0579.2003.00214.x · Cited by 35 · cited 1×
“Previous studies in postmenopausal women (8, 19–22) and in women with type 2 diabetes (9) have demonstrated that raloxifene exerts no effect on carbohydrate metabolism (9, 10, 21, 22) or insulin sensitivity (19, 20).”
BackgroundOleksik, A. M., Duong, T., Pliester, N., Asma, G. B., Popp‐Snijders, C., & Lips, P. T. A. M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7549 · Cited by 35 · cited 2×
“Raloxifene has been shown to reduce IGF-I in healthy postmenopausal women (7, 8), women with breast cancer (16), and men and women with acromegaly (17, 18).”
BackgroundRaloxifene Does Not Modify Insulin Sensitivity and Glucose Metabolism in Postmenopausal Women
Cagnacci, A., Paoletti, A. M., Zanni, A., Arangino, S., Ibba, G., Orrù, M., Melis, G. B., & Volpe, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020120 · Cited by 31
Scharf, J., Ramadori, G. P., Braulke, T., & Hartmann, H. (1995) · Progress in Growth Factor Research · doi:10.1016/0955-2235(95)00031-3 · Cited by 29
Cucinelli, F., Soranna, L., Romualdi, D., Muzj, G., Mancuso, S., & Lanzone, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011302 · Cited by 29
Vankrunkelsven, P., & Thijs, M. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91820-1 · Cited by 26
Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women
Lasco, A., Gaudio, A., Morabito, N., Previti, M., Mileto, A., Frisina, N., & Cucinotta, D. (2004) · Diabetologia · doi:10.1007/s00125-004-1328-4 · Cited by 20 · cited 1×
“Previous studies in postmenopausal women (8, 19–22) and in women with type 2 diabetes (9) have demonstrated that raloxifene exerts no effect on carbohydrate metabolism (9, 10, 21, 22) or insulin sensitivity (19, 20).”
BackgroundDuschek, E. J. J., Roo, G. W. D. V.-D., Gooren, L. J., & Netelenbos, J. C. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.01.033 · Cited by 17 · cited 7×
“00/0 The Journal of Clinical Endocrinology & Metabolism 90(7):3897–3903”
BackgroundInfluentialSelective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
(2003) · New England Journal of Medicine · doi:10.1056/nejm200303203481230 · Cited by 16
O'Sullivan, A. J., Crampton, L., Freund, J., & Ho, K. K. Y. (1996) · Maturitas · doi:10.1016/s0378-5122(97)81064-x · Cited by 11
Self-citationSerum Estradiol Level and Risk of Breast Cancer During Treatment With Raloxifene
Cummings, S. R., Duong, T., Kenyon, E., Cauley, J. A., Whitehead, M. I., & Krueger, K. A. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200205000-00020 · Cited by 7
Weissberger, A. J., Ho, K. K. Y., & Lazarus, L. (1991) · Maturitas · doi:10.1016/0378-5122(91)90161-i · Cited by 5 · cited 3×
“The influence of estrogens on the GH/IGF-I axis is dose dependent and is dictated by effects exerted on the liver (2, 4, 15).”
BackgroundSelf-citation
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Modulation of growth hormone action by sex steroids
Meinhardt, U. J., & Ho, K. K. Y. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02676.x · Cited by 225
Self-citationThe Growth Hormone/Insulin-Like Growth Factor-I Axis in Exercise and Sport
Gibney, J., Healy, M.-L., & Sönksen, P. H. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0052 · Cited by 178
Self-citationSex Differences in Energy Metabolism Need to Be Considered with Lifestyle Modifications in Humans
Wu, B. N., & O’Sullivan, A. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/391809 · Cited by 191
“oestrogen therapy [28].”
Growth hormone and physical performance
Birzniece, V., Nelson, A. E., & Ho, K. K. Y. (2011) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2011.02.005 · Cited by 79
Self-citation
Metadata
- Authors
- Gibney, J., Johannsson, G., Leung, K.-C., & Ho, K. K. Y.
- Affiliations
- Garvan Institute of Medical Research (AU)
- St Vincent's Hospital Sydney (AU)
- Corresponding author
- Ho, Ken K. Y.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-07
- Volume
- 90
- Issue
- 7
- Pages
- 3897-3903
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2160962105
- Semantic Scholar
- 0d259599a38ee5d231df313ff6c713ba690bc525
- Cited by
- 40
- References
- 42
- Citations by year
- 2023: 1 · 2021: 1 · 2018: 1 · 2017: 4 · 2016: 2 · 2015: 2 · 2013: 3 · 2012: 4
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- raloxifene, estradiol, selective estrogen receptor modulators, growth hormone deficiency, hypopituitarism, postmenopausal women, insulin-like growth factor I, IGFBP-3, fat oxidation, hepatic metabolism, liver function, sex hormone-binding globulin, GH-binding protein
- MeSH terms
- Adolescent, Adult, Energy Metabolism, Estradiol, Female, Humans, Insulin-Like Growth Factor I, Middle Aged, Oxidation-Reduction, Sex Hormone-Binding Globulin, Postmenopause, Cross-Over Studies, Insulin-Like Growth Factor Binding Protein 3, Human Growth Hormone, Raloxifene Hydrochloride, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.